The role of T-type calcium channels in peripheral and central pain processing
- PMID: 17168748
- DOI: 10.2174/187152706779025490
The role of T-type calcium channels in peripheral and central pain processing
Abstract
It is well established that the voltage-gated calcium (Ca2+) channels can modulate neuronal activity in the peripheral and central nervous system causing a variety of behavioral and neuro-endocrine changes in humans and animals. While much attention was focused on the modulation of high voltage-activated (HVA)-type Ca2+ channels, the role of low voltage-activated (LVA) or transient (T) type Ca2+ channels in sensory processing, and in particular pain processing (nociception) is much less certain. However, recent evidence strongly suggests that modulation of both central and peripheral T-type Ca2+ channels influences somatic and visceral nociceptive inputs and that modulation of T-type Ca2+ currents results in significant alteration of pain threshold in a variety of animal pain models. Therefore, T-type Ca2+ channels in peripheral and central neurons, although previously unrecognized, may be important targets for analgesic therapeutic agents including endogenous compounds. Currently available pain therapies remain insufficient with limited efficacy and numerous side effects. Hence, studies of selective and potent modulators of neuronal T-type Ca2+ channels may greatly aid in revealing roles for these channels in sensory pathways (nociception in particular) and in the development of novel and potentially more effective and safer pain therapies. In the present review, we summarize the putative role of peripheral and central T-type Ca2+ channels in nociception and our recent in vivo and in vitro studies focusing primarily on 5alpha- and 5beta-reduced neuroactive steroids and redox agents that are potent modulators of neuronal T-type Ca2+ channels.
Similar articles
-
New evidence that both T-type calcium channels and GABAA channels are responsible for the potent peripheral analgesic effects of 5alpha-reduced neuroactive steroids.Pain. 2005 Apr;114(3):429-443. doi: 10.1016/j.pain.2005.01.009. Pain. 2005. PMID: 15777868
-
Regulation of T-type calcium channels in the peripheral pain pathway.Channels (Austin). 2007 Jul-Aug;1(4):238-45. doi: 10.4161/chan.4953. Epub 2007 Oct 1. Channels (Austin). 2007. PMID: 18708751 Review.
-
The role of peripheral T-type calcium channels in pain transmission.Cell Calcium. 2006 Aug;40(2):197-203. doi: 10.1016/j.ceca.2006.04.024. Epub 2006 Jun 13. Cell Calcium. 2006. PMID: 16777222 Review.
-
T-type voltage-gated calcium channels as targets for the development of novel pain therapies.Br J Pharmacol. 2011 Jun;163(3):484-95. doi: 10.1111/j.1476-5381.2011.01256.x. Br J Pharmacol. 2011. PMID: 21306582 Free PMC article. Review.
-
5beta-reduced neuroactive steroids are novel voltage-dependent blockers of T-type Ca2+ channels in rat sensory neurons in vitro and potent peripheral analgesics in vivo.Mol Pharmacol. 2004 Nov;66(5):1223-35. doi: 10.1124/mol.104.002402. Epub 2004 Jul 27. Mol Pharmacol. 2004. PMID: 15280444
Cited by
-
Sumatriptan inhibition of N-type calcium channel mediated signaling in dural CGRP terminal fibres.Neuropharmacology. 2012 Sep;63(3):362-7. doi: 10.1016/j.neuropharm.2012.04.016. Neuropharmacology. 2012. PMID: 22691374 Free PMC article.
-
The development of chronic pain: physiological CHANGE necessitates a multidisciplinary approach to treatment.Curr Med Res Opin. 2013 Sep;29(9):1127-35. doi: 10.1185/03007995.2013.810615. Epub 2013 Jul 3. Curr Med Res Opin. 2013. PMID: 23786498 Free PMC article. Review.
-
Expression and Regulation of Cav3.2 T-Type Calcium Channels during Inflammatory Hyperalgesia in Mouse Dorsal Root Ganglion Neurons.PLoS One. 2015 May 14;10(5):e0127572. doi: 10.1371/journal.pone.0127572. eCollection 2015. PLoS One. 2015. PMID: 25974104 Free PMC article.
-
Assessment of the effectiveness and safety of ethosuximide in the treatment of abdominal pain related to irritable bowel syndrome - IBSET: protocol of a randomised, parallel, controlled, double-blind and multicentre trial.BMJ Open. 2017 Jul 18;7(7):e015380. doi: 10.1136/bmjopen-2016-015380. BMJ Open. 2017. PMID: 28720615 Free PMC article. Clinical Trial.
-
Preparation and Functional Identification of a Novel Conotoxin QcMNCL-XIII0.1 from Conus quercinus.Toxins (Basel). 2022 Jan 26;14(2):99. doi: 10.3390/toxins14020099. Toxins (Basel). 2022. PMID: 35202127 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous